The Lash List Editorial Team Not medically reviewed

What Is Isopropyl Cloprostenate in Lash Serum?

Plain answer: Isopropyl cloprostenate is a lab-made prostaglandin analogue in some lash serums. It is not bimatoprost, the drug in LATISSE. Health Canada lists this ingredient family as prohibited in cosmetics. In 2026, an EU science panel reviewed this exact name. It said the ingredient could not be considered safe for lash and brow growth products.

Review status: This is a source-checked editorial draft. Qualified review required before indexation. An ophthalmologist or optometrist must review ocular and drug claims. A dermatologist or cosmetic toxicology expert must review claims within their scope.

Quick facts

Exact nameIsopropyl Cloprostenate
Source abbreviationIPCP in SCCS/1680/25. A source may use a different shorthand, so retain the full INCI name.
Ingredient classProstaglandin analogue.
Drug statusIt is not the FDA-approved prescription eyelash ingredient bimatoprost.
Effectiveness evidence gradeE for an ingredient-specific human eyelash claim based on the public sources reviewed here.
Source check2026-07-11

Does isopropyl cloprostenate grow eyelashes?

Brands use it in lash-enhancing formulas and describe it as a prostaglandin analogue. That establishes intended use, not an independent clinical effect size. Our source review did not find a controlled human eyelash trial that isolated isopropyl cloprostenate from the rest of a finished formula.

The SCCS opinion described prostaglandin analogues as having potent pharmacological activity, even at low concentrations. Pharmacological activity is not the same as a proven cosmetic benefit, and it does not establish how much growth a particular serum will produce.

Effectiveness evidence

The Lash List editorial grade key: A = strong controlled human evidence for the exact use. B = one controlled human study. C = a small uncontrolled human formula study. D = laboratory, animal, scalp-hair, or supplier evidence. E = label presence, theory, or no direct human eyelash evidence. This is our editorial rubric, not a recognized clinical grading system. Grades do not rate safety.

EvidenceEvidence gradeWhat it can support
Current official brand labels list the ingredient in lash serums.EPresence and intended cosmetic use only.
Brand consumer studies on multi-ingredient products.DWhat the named finished formula reported, if methods are available. They cannot isolate this ingredient.
Similarity to another prostaglandin analogue.EA mechanism hypothesis, not equal efficacy.

Safety assessment

Assessment statusCould not be considered safe for cosmetic products intended to promote eyelash or eyebrow growth in the 2026 SCCS opinion; prohibited within Health Canada's prostaglandin cosmetic entry.
AuthoritySCCS final opinion SCCS/1680/25 and Health Canada Cosmetic Ingredient Hotlist.
ScopeCosmetic eyelash and eyebrow growth use. SCCS considered a proposed maximum concentration of 0.005% for IPCP.
JurisdictionEuropean Union scientific advice and Canadian cosmetic requirements. No global status is implied.
Known effectsThe sources establish potent pharmacological activity and a safety concern. Bimatoprost label effects cannot be assigned the same incidence to IPCP.
Data gapsAcceptable reproductive and developmental toxicity data, long-term eye-area exposure, independent human eyelash efficacy, and formula-specific concentration data.
Checked date2026-07-11

What did SCCS conclude in 2026?

SCCS evaluated evidence submitted for IPCP, MDN, and DDDE. It concluded that none could be considered safe for cosmetic products intended to promote eyelash or eyebrow growth. The committee cited potent pharmacological activity and a lack of acceptable data that could exclude potential reproductive or developmental effects.

The careful wording matters. Could not be considered safe does not mean a study proved that every user will be harmed. It means the evidence package did not support the requested safety conclusion. The opinion is scientific advice, not the text of an EU prohibition.

What does Health Canada say?

Health Canada's prohibited cosmetic list includes prostaglandins, their salts, derivatives, and analogues. Isopropyl cloprostenate is named in that entry. Health Canada explains that prohibited ingredients should not be present in cosmetics sold in Canada.

Which current labels list it?

The following examples come from official brand ingredient pages checked on 2026-07-11. They establish label presence only. They do not establish concentration, safety, or which ingredient caused a product result.

Product labelOfficial sourceChecked
GrandeLASH-MDGrande Cosmetics ingredient list2026-07-11
RapidLash Eyelash Enhancing SerumRapidLash ingredient list2026-07-11
Babe Original Essential Lash SerumBabe Original ingredient list2026-07-11

Formulas can change by date and market. Check the package you will use. Do not rely on an old review screenshot or an undated retailer list.

Is it the same as bimatoprost?

No. Both belong to the wider prostaglandin analogue conversation, but they are different chemicals. Bimatoprost 0.03% has a prescription label and controlled human eyelash evidence. IPCP does not inherit that approval, dose, trial result, or adverse-reaction rate.

What should a shopper do?

  • Look for the full name Isopropyl Cloprostenate on the current package.
  • Do not use label position to guess concentration.
  • Use the Ingredient Checker only as a name screen.
  • Read the ingredient risk guide and ask an eye clinician if you have an eye condition or use glaucoma medicine.

Sources and evidence limits

Product label example

Grande Cosmetics' current official U.S. ingredient list names isopropyl cloprostenate. This label match does not prove how much is present or predict one person's result. Source checked July 11, 2026; formulas can change.

Related ingredient pages

Use the evidence system

Return to the lash serum ingredient hub, paste a current ingredient label into the checker, or read the ingredient risk guide.

This page is educational. It does not diagnose an eye condition or replace advice from a qualified clinician.